These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27983726)

  • 1. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.
    Takamatsu H; Honda S; Miyamoto T; Yokoyama K; Hagiwara S; Ito T; Tomita N; Iida S; Iwasaki T; Sakamaki H; Suzuki R; Sunami K
    Cancer Sci; 2015 Feb; 106(2):179-85. PubMed ID: 25530023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
    Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
    Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Haematologica; 2017 Aug; 102(8):1439-1445. PubMed ID: 28473618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
    Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
    BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
    Li Q; Ai L; Zuo L; Li J; Zhao F; Xu A; Zhang B; Cai L; Hu Y; Sun C
    Ann Med; 2024 Dec; 56(1):2338604. PubMed ID: 38599340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
    Kapoor P; Kumar SK; Dispenzieri A; Lacy MQ; Buadi F; Dingli D; Russell SJ; Hayman SR; Witzig TE; Lust JA; Leung N; Lin Y; Zeldenrust SR; McCurdy A; Greipp PR; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2013 Dec; 31(36):4529-35. PubMed ID: 24248686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation for multiple myeloma: Long-term results.
    Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
    Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
    Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
    Sidana S; Tandon N; Dispenzieri A; Gertz MA; Dingli D; Jevremovic D; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Hobbs M; Fonder A; Kyle RA; Rajkumar SV; Kumar SK; Gonsalves WI
    Leukemia; 2018 Jun; 32(6):1421-1426. PubMed ID: 29483709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.